Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192608 | 0.83 | HTR1A (0.34) | HTR1AHCRTR1HCRTR2DRD2 | |
| SCHEMBL10192607 | 0.75 | ALK (0.49) | — | |
| SCHEMBL659592 | 0.72 | HCRTR2 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL7119967 | 0.61 | NPC1 (0.41) | — | |
| SCHEMBL15577211 | 0.57 | DRD2 (0.55) | HTR1ADRD2 | |
| SCHEMBL30563675 | 0.57 | HTR1A (0.42) | HTR1ADRD2 | |
| SCHEMBL26962732 | 0.57 | HTR1A (0.42) | HTR1ADRD2 | |
| SCHEMBL27118897 | 0.57 | HTR1A (0.42) | HTR1ADRD2 | |
| SCHEMBL17014302 | 0.56 | HTR1A (0.50) | HTR1ADRD2 | |
| SCHEMBL265887 | 0.56 | ACHE (0.58) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | HTR1A 96/4885HCRTR1 313/4885HCRTR2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.